ABSTRACT: IBD (inflammatory bowel diseases) represent chronic idiopathic inflammatory diseases, prone to relapse in the digestive tract; it is estimated that they result from the interaction of the intestinal microbiome with the intestinal immune system. The inflammatory microbiome exerts multiple beneficial roles. Perhaps the central element to developing IBD is dysbiosis; there is still an incompletely established association between intestinal microbiome changes in patients with IBD and SIBO (small intestinal bacterial overgrowth). Influencing the intestinal microbiome may play an adjuvant therapeutic role in the treatment of IBD. We present a synthesis of the connections between the entities mentioned above.
Intestinal Microbiome
The small intestine is, from a microbiological point of view, a transitional area between the stomach (under 10 3 colony forming units/ ml) and colon (approximately 10 12 microorganisms per gram of colonic content), which comprises more than 1000 different species of microorganisms.
The number of microbial species present in the human gastrointestinal tract is estimated to range between 1000-1150; at the same time, there are at least 160 species coexisting in every individual [1, 2] .
The intestinal microbiome presents multiple roles -summarized in Table 1 . • biological transformation of bile salts [5] • adjuvant in the metabolism of certain drugs (sulfasalazine, digoxin) [5] There is some data in the literature on differences between the microbiome of obese individuals and individuals with normal body weight, which could lead to differences in caloric extraction from ingested food [5, 6, 7] .
The most important species are Firmicutes and Bacteroidetes, Proteibacteria and Actinobacteria, Veruccomicrobia and Fusobacteria [2, 8] . Some of these species are considered to exert anti-inflammatory and antitumorigenic roles, as well as inhibition of pathogens: bacteria producing butyrate (Faecalibacterium prausnitzii, Roseburia spp) and those producing lactic acid (Lactobacillus and Bifidobacterium) [2, 9] .
SIBO (small intestinal bacterial overgrowth)
SIBO is characterized by bacterial overpopulation of the small bowel [10] or by alterations in the type and ratio of these microorganisms [11] . The classic definition is represented by the presence of at least 10 5 CFU/ml of intestinal aspirate. 
Intestinal Microbiome and IBD
IBD (ulcerative colitis-UC and Crohn's Disease-CD) are chronic idiopathic diseases, prone to relapse in the digestive tract, and considered at the moment to be a result of the interaction between intestinal microbiome and intestinal immune system [22, 23] . The composition of the intestinal microbiome influences susceptibility to develop IBD [24] .
There is important evidence on the involvement of the intestinal microbiome in the pathogenesis of IBD; experimental findings that mice lacking intestinal germs do not develop severe colitis come to support this hypothesis [25] .
Dysbiosis (altering the intestinal microbiome ratio) is probably central to developing IBD [26] . In IBD, microbiome diversity is limited.
Intestinal microbiome changes in IBD and some consequences are represented in Table 2 .
Pathogenic microorganisms associated with IBD are:
Mycobacterium avium paratuberculosis (MAP)-can be isolated from water, milk and meat and is resistant to pasteurization. It seems that the incidence of positive samples of MAP is no higher in CD than in the control population if we refer to faeces tests, but is significantly increased when the comparison is made by biopsy of the distal ileum or colon [2, 37, 38] . However, the role of MAP in the aetiology of inflammatory diseases remains uncertain.
Helicobacter seems to be negatively associated with IBD [26] . Hepaticus, bilis, trogontum and rodentium species apparently induce an immune response against commensal bacteria, and secondary immune-mediated intestinal inflammation [26, 39] . Adherent invasive Escherichia coli (AIEC)-adhere and invade the epithelial cells. Prevalence of AIEC in ileal biopsies of patients with Crohn's disease is significantly higher than in control patients (36.4% vs. 6.2%) [40] .
Clostridium difficile is incriminated in inflammatory disease flares, with rates varying widely between 5-60% [41] . Administration of immunosuppressive drugs increases the risk by 2-3 times. Currently, it is unclear whether C. difficile contributes to the intestinal inflammation characteristic of IBD or patients with such diseases are susceptible to infection with C. difficile [2] .
Campylobacter-with its species, ureolitycus and concisus, alongside jejuni, can alter the intestinal barrier by translocation of commensal bacteria [2, 42, 43] . In a survey from 2011 [44] a several times increase in the risk of developing Crohn's disease was demonstrated in the first year, as well as the next 10 years, after acute infection with C. jejuni.
Salmonella. In a 2011 study [44] it was shown that infection with non-typhoid strains of Salmonella increases the risk of both ulcerative colitis and Crohn's disease in the first year after infection (5.4 times higher risk in the first year and 1.6 times in the next 10 years).
Other microorganisms. Epstein Barr virus can promote inflammation and increase multiplication in B lymphocytes [2, 45] . Recently, the presence of Fusobacterium varium in significantly higher titre has been demonstrated in patients with UC [46] . Anti-K. pneumoniae antibodies are more common in patients with IBD (the severity of colonic inflammation increases in experimental models, the expression of IL-1β, IL-6 and TNF-α increases) [26, 47] . Other possibly involved microorganisms: CMV, Candida albicans -the exact role has not yet been established.
SIBO and IBD
Causes of SIBO development in patients with IBD are multiple: postoperative absence of the ileo-cecal valve, presence of entero-colonic fistulas, motility disorders, intestinal strictures, alterations in the intestinal microbiome.
In current clinical practice, the use of respiratory H 2 tests presents high diagnostic accuracy, which is why it is commonly employed for highlighting SIBO.
In a 2009 study, Klaus et al [48] identified a prevalence of 25.3% of SIBO in patients with diagnosis of Crohn's disease, who reported an increase in the daily number of stools or flatulence. SIBO patients presented on average more stools/day (5.9 vs.3.7) and a lower body weight (63kg vs. 70kg). The association of SIBO was positive in patients with intestinal resection or mixt intestinal and colonic impairment, but no positive association with Crohn's disease activity index was found.
Changes in the treatment of IBD in recent years have led to the assumption that biological or immunosuppressive medication may increase the risk of infections. Regarding the risk of intestinal bacterial overgrowth, the assumption has recently been refuted; overall prevalence of SIBO in patients in remission was 16.8%, with no noticeable differences between patients under immunosuppressive, biological or mixed treatment [49] .
When using H 2 glucose and lactulose breath tests to highlight SIBO and oro-cecal transit time, one can observe that the oro-cecal transit time was significantly higher in patients with CD compared to those with UC, and the prevalence of SIBO is higher in patients with CD (45.2%) compared to those with UC (17.8%) [50] .
Similar data have been reported in a very recent study [51] : when using HGBT, prevalence of SIBO in patients with IBD is 20.6%, higher in CD versus UC (30.2% vs. 14.1%). [55] .
Influencing the Intestinal Microbiome as a Treatment Modality in IBD
The role of prebiotics Administration of fructo-oligosaccharide in patients with CD apparently has no clinical benefits [56] , but was associated with a significant reduction in Harvey Bradshaw index and an increase in faecal bifidobacteria concentration [57] .
As for UC, different prebiotics proved a certain degree of efficiency: Germinated barley foodstuff and Ispaghula husk are effective in inducing remission in patients with moderate to severe UC [27, 58, 59] ; oligofructose combination with inulin seems to reduce the degree of inflammation [60] ; inulin reduces inflammation in pouchitis [61] .
The role of antibiotics There are numerous data in the literature concerning the effectiveness of metronidazole and ciprofloxacin in the treatment of pouchitis and CD, as well as in UC.
Rifaximin (an antimicrobial agent active in the intestinal lumen) appears to be effective in inducing remission in patients with moderately active CD (remission rates of up to 62% in week 12) [62] . 
Helminth therapy

Conclusions
Involvement of the intestinal microbiome in the aetiology of IBD is an area of great interest, likely to be elucidated in the coming years. Presence of SIBO to a quite important extent creates the possibility of using H 2 breath tests to identify the patients who could benefit from influencing the intestinal microbiome. 
